Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines (Q39343246)

11 September 2017

Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines (English)

1 reference

11 September 2017

Maria Cosenza

1

1 reference

11 September 2017

Monica Civallero

2

1 reference

11 September 2017

Giulia Grisendi

3

1 reference

11 September 2017

Luigi Marcheselli

4

1 reference

11 September 2017

Erika Roat

5

1 reference

11 September 2017

Alessia Bari

6

1 reference

11 September 2017

Stefano Sacchi

7

1 reference

11 September 2017

language of work or name

1 reference

24 May 2012

1 reference

11 September 2017

1 reference

11 September 2017

91

1 reference

11 September 2017

10

1 reference

11 September 2017

1613-1622

1 reference

Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ

11 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Long-term culture of human bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Basis for effective combination cancer chemotherapy with antimetabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

An update on drug combinations for treatment of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1490-6

10.1007/S00277-012-1490-6

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference